drugset / Trial / NCT04630522
Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, open-label, dose-finding, multi-centre, phase Ⅰb study to evaluate the efficacy and safety of JMT103 in patients with bone metastases from solid tumors.
Timeline
- Start
- 2020-10-31
- Primary completion
- 2023-03-31
- Completion
- 2023-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JMT103 | Monoclonal antibody | 120 mg | Subcutaneous |
| Subject | JMT103 | Monoclonal antibody | 180 mg | Subcutaneous |